Corticotropin is a Synthetic Peptide owned by Mallinckrodt, and is involved in 44 clinical trials, of which 38 were completed, and 6 are ongoing.

H.P. Acthar Gel (Corticotropin, Repository Corticotropin) and endogenous adrenocorticotropic hormone ACTH) stimulate the adrenal cortex to secrete cortisol, corticosterone, aldosterone, and a number of weakly androgenic substances. The primary component of Acthar is adrenocorticotropic hormone (ACTH), which is a melanocortin peptide that binds to all 5 melanocortin receptors (MC1R, MC2R, MC3R, MC4R, MC5R) found throughout the body and in a number of brain regions. ACTH binds to melanocortin receptors on the adrenal cortex.Through melanocortin receptor, Acthar stimulates the adrenal cortex to secrete cortisol, corticosterone, aldosterone, and a number of weakly androgenic substances.

The revenue for Corticotropin is expected to reach a total of $731m through 2024. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Corticotropin NPV Report.

Corticotropin is currently owned by Mallinckrodt.

Corticotropin Overview

Corticotropin, Repository Corticotropin (H.P. Acthar/Acthar) is a purified preparation of the adrenocorticotropic hormone (ACTH) obtained from porcine pituitary. It is formulated as injection gel for intramuscular and subcutaneous route of administration and powder for solution for intravenous, intramuscular and subcutaneous routes of administration. It is indicated for the treatment of infantile spasms, multiple sclerosis (acute exacerbations of multiple sclerosis), rheumatic disorders (Psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis, ankylosing spondylitis), collagen diseases (systemic lupus erythematosus, systemic dermatomyositis (polymyositis)), dermatologic diseases (severe erythema multiforme, Stevens-Johnson syndrome), allergic states (Serum sickness), ophthalmic diseases (keratitis, iritis, iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, anterior segment inflammation), respiratory diseases (pulmonary sarcoidosis) and edematous states (proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus). In the treatment of infantile spasms, H.P. Acthar Gel must be administered intramuscularly.

It is under development for the treatment of IgA nephropathy.

The drug candidate was under development for the treatment of amyotrophic lateral sclerosis. It was also under development for the treatment of acute respiratory syndrome, chronic migraine, diabetic nephropathy, and proteinuria. 

Mallinckrodt Overview

Mallinckrodt develops, produces, markets, and distributes specialty pharmaceutical products and therapies. The company offers branded pharmaceutical products for autoimmune and rare diseases in specialty areas such as rheumatology, nephrology, neurology, pulmonology and ophthalmology. It also offers immunotherapy, oncology and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company offers specialty generic drugs and active pharmaceutical ingredients. Mallinckrodt markets branded products directly to physicians, specialty pharmacies, hospitals and ambulatory surgical centers; and also distributes branded and generic products through a network of drug distributors, specialty pharmaceutical distributors and retail pharmacy chains, among others. It has facilities in the US, Ireland, Japan and other countries. Mallinckrodt is headquartered in Dublin, Ireland.

The company reported revenues of (US Dollars) US$2,208.8 million for the fiscal year ended December 2021 (FY2021), a decrease of 19.7% over FY2020. The operating loss of the company was US$631.1 million in FY2021, compared to an operating loss of US$713 million in FY2020. The net loss of the company was US$717.4 million in FY2021, compared to a net loss of US$944.6 million in FY2020.

Quick View – Corticotropin

Report Segments
  • Innovator (NME)
Drug Name
  • Corticotropin
Administration Pathway
  • Intramuscular
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Central Nervous System
  • Dermatology
  • Genito Urinary System And Sex Hormones
  • Immunology
  • Metabolic Disorders
  • Musculoskeletal Disorders
  • Ophthalmology
  • Respiratory
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.